Home › Free Stock Grades › RXRX
Recursion Pharmaceuticals, Inc. (RXRX) Stock Grade
RXRX · Healthcare
B+
Market Cap
$1.8B
P/E Ratio
—
Revenue Growth (YoY)
+26.9%
Net Margin
-863.4%
Return on Equity
—
Dividend Yield
None
About Recursion Pharmaceuticals, Inc.'s fundamentals
Recursion Pharmaceuticals is a biotech company with a $1.8 billion market cap that is experiencing strong revenue growth of 26.9% year-over-year, indicating expanding business activity. However, the company is currently unprofitable, with a net margin of -863.4% and a reported net loss in its latest annual statement, reflecting the typical capital-intensive development phase of biotechnology firms. The company does not pay a dividend, which is common for growth-stage biotech companies that reinvest available resources into research and development.